Clinical and histologic implications of delayed hepatobiliary enhancement on magnetic resonance imaging with gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid

Investigative Radiology

Volumn 47, Issue 11, 2012, Pages 649-655

  Chen, Bang Bin ^a   Hsu, Chao Yu ^a   Yu, Chih Wei ^a   Wei, Shwu Yuan ^a   Kao, Jia Horng ^a   Lee, Hsuan Shu ^a   Shih, Tiffany Ting Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

contrast media; Gd EOB DTPA; hepatitis; liver cirrhosis; magnetic resonance imaging

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GADOXETIC ACID; HEMOGLOBIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY MASS; BODY WEIGHT; CHRONIC HEPATITIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEPATIC DUCT; HEPATOBILIARY SYSTEM EXAMINATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSTITUTIONAL REVIEW; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER FIBROSIS; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; NONPARAMETRIC TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTHROMBIN TIME; RECEIVER OPERATING CHARACTERISTIC; THROMBOCYTE COUNT;

EID: 84867274638     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3182652fb9     Document Type: Article

References (36)

1. Kitao A, Matsui O, Yoneda N, et al. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol. 2011;21:2056-2066.
2. Takao H, Akai H, Tajima T, et al. MR imaging of the biliary tract with Gd-EOBDTPA: effect of liver function on signal intensity. Eur J Radiol. 2011;77: 325-329.
3. Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imagingVcorrelation with molecular transporters and histopathologic features. Radiology. 2010;256:817-826.
4. Lee NK, Kim S, Lee JW, et al. Biliary MR imaging with Gd-EOB-DTPA and its clinical applications. Radiographics. 2009;29:1707-1724.
5. Smith AD, Veniero JC. Gd-EOB-DTPA as a functional MR cholangiography contrast agent: imaging gallbladder filling in patients with and without hepatobiliary d-Sfunction. J Comput Assist Tomogr. 2011;35:439-445.
6. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995;195:785-792.
7. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology. 1996;199: 177-183.
8. Tamada T, Ito K, Higaki A, et al. Gd-EOB-DTPA-enhanced MR imaging: Evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur J Radiol. 2011;80:e311-e316.
9. Motosugi U, Ichikawa T, Oguri M, et al. Staging liver fibrosis by using liverenhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging. 2011; 29:1047-1052.
10. Goshima S, Kanematsu M,Kobayashi T, et al. Staging hepatic fibrosis: computeraided anal-Sis of hepatic contours on gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid-enhanced hepatocyte-phase magnetic resonance imaging. Hepatology. 2012;55:328-329.
11. Chen BB, Hsu CY, Yu CW, et al. Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients. Eur Radiol. 2012;22:171-180.
12. Tschirch FT, Struwe A, Petrowsky H, et al. Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol. 2008;18:1577-1586.
13. Watanabe H, Kanematsu M, Goshima S, et al. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imagingV preliminary observations. Radiology. 2011;259:142-150.
14. Seo HJ, Kim MJ, Lee JD, et al. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases. Invest Radiol. 2011;46:548-555.
15. Kim YK, Kim CS, Han YM, et al. Detection of small hepatocellular carcinoma: intraindividual comparison of gadoxetic acid-enhanced MRI at 3.0 and 1.5 T. Invest Radiol. 2011;46:383-389.
16. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (G or = 2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol. 2010;45:96-103.
17. Kim YK, Kim CS, Han YM, et al. Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging? Invest Radiol. 2010;45:740-746.
18. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol. 2010;45:133-141.
19. Motosugi U, Ichikawa T, Onohara K, et al. Distinguishing hepatic metastasis from hemangioma using gadoxetic acid-enhanced magnetic resonance imaging. Invest Radiol. 2011;46:359-365.
20. Lowe A, Breuer J, Palkowitsch P. Evaluation of the effect of two gadoliniumcontaining contrast-enhancing agents, gadobutrol and gadoxetate disodium, on colorimetric calcium determinations in serum and plasma. Invest Radiol. 2011;46:366-369.
21. Sofue K, Tsurusaki M, Tokue H, et al. Gd-EOB-DTPA-enhanced 3.0 T MR imaging: quantitative and qualitative comparison of hepatocyte-phase images obtained 10 min and 20 min after injection for the detection of liver metastases from colorectal carcinoma. Eur Radiol. 2011;21:2336-2343.
22. Motosugi U, Ichikawa T, Sano K, et al. Double-dose gadoxetic acid-enhanced magnetic resonance imaging in patients with chronic liver disease. Invest Radiol. 2011;46:141-145.
23. Feuerlein S, Boll DT, Gupta RT, et al. Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein. AJR Am J Roentgenol. 2011;196:W18-W24.
24. Zech CJ, Vos B, Nordell A, et al. Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol. 2009;44:305-310.
25. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring s-Stem for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-435.
26. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24: 289-293.
27. Gault MH, Longerich LL, Harnett JD, et al. Predicting glomerular function from adjusted serum creatinine. Nephron. 1992;62:249-256.
28. R-eom HK, Kim SH, Kim JY, et al. Quantitative evaluation of liver function with MRI using Gd-EOB-DTPA. Korean J Radiol. 2004;5:231-239.
29. Kim T, Murakami T, Hasuike Y, et al. Experimental hepatic d-Sfunction: evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging. 1997;7: 683-688.
30. Katsube T, Okada M, Kumano S, et al. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol. 2011;46:277-283.
31. Gschwend S, Ebert W, Schultze-Mosgau M, et al. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol. 2011;46:556-566.
32. Tajima T, Takao H, Akai H, et al. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr. 2010;34:362-366.
33. Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging. 2009;30:1042-1046.
34. Motosugi U, Ichikawa T, Tominaga L, et al. Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time? Eur Radiol. 2009;19:2623-2629.
35. Frericks BB, Loddenkemper C, Huppertz A, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol. 2009;193:1053-1060.
36. Moriyama Y, Saito S, Kobayashi S, et al. Evaluation of concanavalin AYinduced acute liver injury in rats using an empirical mathematical model and dynamic contrast-enhanced MR imaging with Gd-EOB-DTPA. Magn Reson Med Sci. 2012;11:53-60.